Literature DB >> 8347561

Mouse CD4 binds MHC class II with extremely low affinity.

S Weber1, K Karjalainen.   

Abstract

Interaction of CD4 with MHC class II molecules plays a crucial role during thymic development and activation of single-positive CD4 T lymphocytes. The quantitation of this interaction is, therefore, important for understanding the role of CD4 during these events. To this end, we have developed a rosette assay, which enabled us to study this molecular interaction. By coupling soluble mouse CD4 onto beads, we could show specific binding of CD4 to MHC class II molecules on A20 B lymphoma cells. These binding studies revealed an extremely low affinity (Ka < or = 10(4) M-1) between CD4 and MHC class II molecules in mouse.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8347561     DOI: 10.1093/intimm/5.6.695

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  17 in total

Review 1.  CD4 on the road to coreceptor status.

Authors:  Dario A A Vignali
Journal:  J Immunol       Date:  2010-06-01       Impact factor: 5.422

2.  Oligomerization of CD4 is required for stable binding to class II major histocompatibility complex proteins but not for interaction with human immunodeficiency virus gp120.

Authors:  T Sakihama; A Smolyar; E L Reinherz
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-03       Impact factor: 11.205

3.  CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics.

Authors:  P A van der Merwe; D L Bodian; S Daenke; P Linsley; S J Davis
Journal:  J Exp Med       Date:  1997-02-03       Impact factor: 14.307

4.  Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells.

Authors:  Gautam K Sahu; Kaori Sango; Nithianandan Selliah; Qiangzhong Ma; Gail Skowron; Richard P Junghans
Journal:  Virology       Date:  2013-09-06       Impact factor: 3.616

Review 5.  LAG3 (CD223) as a cancer immunotherapy target.

Authors:  Lawrence P Andrews; Ariel E Marciscano; Charles G Drake; Dario A A Vignali
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

6.  A computer screening approach to immunoglobulin superfamily structures and interactions: discovery of small non-peptidic CD4 inhibitors as novel immunotherapeutics.

Authors:  S Li; J Gao; T Satoh; T M Friedman; A E Edling; U Koch; S Choksi; X Han; R Korngold; Z Huang
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-07       Impact factor: 11.205

7.  LAG3 ectodomain structure reveals functional interfaces for ligand and antibody recognition.

Authors:  Qianqian Ming; Daiana P Celias; Chao Wu; Aidan R Cole; Srishti Singh; Charlotte Mason; Shen Dong; Timothy H Tran; Gaya K Amarasinghe; Brian Ruffell; Vincent C Luca
Journal:  Nat Immunol       Date:  2022-06-27       Impact factor: 31.250

Review 8.  Signal initiation in biological systems: the properties and detection of transient extracellular protein interactions.

Authors:  Gavin J Wright
Journal:  Mol Biosyst       Date:  2009-12

9.  Potent T cell activation with dimeric peptide-major histocompatibility complex class II ligand: the role of CD4 coreceptor.

Authors:  A R Hamad; S M O'Herrin; M S Lebowitz; A Srikrishnan; J Bieler; J Schneck; D Pardoll
Journal:  J Exp Med       Date:  1998-11-02       Impact factor: 14.307

10.  Weak self-association in a carbohydrate system.

Authors:  Trushar R Patel; Stephen E Harding; Anna Ebringerova; Marcin Deszczynski; Zdenka Hromadkova; Adiaratou Togola; Berit Smestad Paulsen; Gordon A Morris; Arthur J Rowe
Journal:  Biophys J       Date:  2007-05-04       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.